
If successful in trials, such drugs could reach the Russian market in 7-10 years.
Photo Credit: Vladimir Petrov
Scientific Frontline: Extended "At a Glance" Summary
The Core Concept: Researchers at Ural Federal University (UrFU) have synthesized a new family of chemical compounds that selectively target and suppress the growth of specific tumor cells by halting their division rather than immediately destroying them.
Key Distinction/Mechanism: Unlike traditional chemotherapy drugs that are often cytotoxic (cell-killing) and harmful to healthy tissues, these new compounds utilize a cytostatic mechanism. They effectively "freeze" the tumor by blocking Cyclin-dependent kinase 2 (CDK2), a protein critical for cell division, thereby preventing tumor proliferation with reduced toxicity to healthy cells.
Origin/History:
- Discovery Context: Developed by the UrFU Scientific, Educational and Innovative Center of Chemical and Pharmaceutical Technologies.
- Publication: Findings and descriptions of the compounds were published in the international journal ChemMedChem.
- Timeline: Announced in February 2026, with potential market availability estimated in 7-10 years pending successful trials.


.jpg)
.jpg)




